Janus Henderson Group PLC Incyte Corp Transaction History

Janus Henderson Group PLC

$182 Billion
Q2 2024

A detailed history of Janus Henderson Group PLC transactions in Incyte Corp stock. As of the latest transaction made, Janus Henderson Group PLC holds 182,681 shares of INCY stock, worth $15.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

182,681

Previous 20,435 793.96%

Holding current value

$15.2 Million

Previous $1.16 Million 851.37%

% of portfolio

0.01%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$51.18 - $63.75 $8.3 Million - $10.3 Million	162,246 Added 793.96%	182,681 $11.1 Million
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $446,462 - $525,728	-7,895 Reduced 27.87%	20,435 $1.16 Million
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $216,307 - $266,195	4,147 Added 17.15%	28,330 $1.78 Million
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $112,478 - $128,365	-1,947 Reduced 7.45%	24,183 $1.4 Million
Q2 2023 Aug 14, 2023	SELL	$60.95 - $75.51 $125,496 - $155,475	-2,059 Reduced 7.3%	26,130 $1.63 Million
Q1 2023 May 15, 2023	SELL	$70.23 - $86.01 $2.63 Million - $3.22 Million	-37,389 Reduced 57.01%	28,189 $2.04 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $2.84 Million - $3.55 Million	42,216 Added 180.7%	65,578 $5.27 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $4.65 Million - $5.82 Million	-70,279 Reduced 75.05%	23,362 $1.56 Million
Q2 2022 Aug 15, 2022	BUY	$66.18 - $83.18 $3.87 Million - $4.86 Million	58,437 Added 166.0%	93,641 $7.11 Million
Q1 2022 May 16, 2022	SELL	$66.02 - $79.71 $559,189 - $675,143	-8,470 Reduced 19.39%	35,204 $2.8 Million
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $302,131 - $353,504	4,770 Added 12.26%	43,674 $3.21 Million
Q3 2021 Nov 16, 2021	BUY	$68.67 - $84.02 $1.19 Million - $1.45 Million	17,263 Added 79.77%	38,904 $2.68 Million
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $1.82 Million - $1.99 Million	-22,746 Reduced 51.24%	21,641 $1.82 Million
Q1 2021 May 17, 2021	SELL	$76.02 - $100.5 $492,837 - $651,541	-6,483 Reduced 12.74%	44,387 $3.61 Million
Q4 2020 Feb 16, 2021	SELL	$80.74 - $97.7 $5.44 Million - $6.58 Million	-67,390 Reduced 56.98%	50,870 $4.42 Million
Q3 2020 Nov 16, 2020	SELL	$85.07 - $109.69 $6.21 Million - $8.01 Million	-73,017 Reduced 38.17%	118,260 $10.6 Million
Q2 2020 Aug 14, 2020	BUY	$74.18 - $108.93 $8.28 Million - $12.2 Million	111,650 Added 140.22%	191,277 $19.9 Million
Q1 2020 May 14, 2020	SELL	$63.18 - $85.97 $2.49 Million - $3.39 Million	-39,398 Reduced 33.1%	79,627 $5.83 Million
Q4 2019 Feb 18, 2020	SELL	$73.04 - $95.72 $13.4 Million - $17.6 Million	-183,553 Reduced 60.66%	119,025 $10.4 Million
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $3.76 Million - $4.47 Million	51,665 Added 20.59%	302,578 $0
Q2 2019 Jul 31, 2019	BUY	$73.52 - $88.7 $10.4 Million - $12.5 Million	141,216 Added 128.73%	250,913 $21.3 Million
Q1 2019 Apr 30, 2019	BUY	$63.56 - $88.17 $4.15 Million - $5.75 Million	65,241 Added 146.75%	109,697 $9.44 Million
Q4 2018 Feb 06, 2019	SELL	$58.5 - $69.94 $12,636 - $15,107	-216 Reduced 0.48%	44,456 $2.83 Million
Q3 2018 Nov 09, 2018	SELL	$61.75 - $74.23 $430,829 - $517,902	-6,977 Reduced 13.51%	44,672 $3.09 Million
Q2 2018 Aug 10, 2018	SELL	$60.85 - $83.98 $22.3 Million - $30.8 Million	-366,259 Reduced 87.64%	51,649 $3.46 Million
Q1 2018 May 14, 2018	SELL	$83.06 - $100.98 $22.7 Million - $27.6 Million	-273,230 Reduced 39.53%	417,908 $34.8 Million
Q4 2017 Feb 09, 2018	SELL	$93.56 - $116.6 $28.1 Million - $35 Million	-300,060 Reduced 30.27%	691,138 $65.5 Million
Q3 2017 Nov 14, 2017	SELL	$109.15 - $138.27 $5.91 Million - $7.49 Million	-54,165 Reduced 5.18%	991,198 $0
Q2 2017 Aug 17, 2017	BUY	N/A	1,045,363	1,045,363 $132 Million

Others Institutions Holding INCY

# of Institutions

629

Shares Held

198M

Call Options Held

763K

Put Options Held

476K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $18.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Incyte Corp Transaction History